Ofatumumab: a novel monoclonal anti-CD20 antibody

Ofatumumab, a novel humanized monoclonal anti-CD20 antibody, was recently approved by the FDA for the treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL). Ofatumumab effectively induces complement-dependent cytotoxicity (CDC) in vitro, and recent studies demonstrat...

Descripción completa

Detalles Bibliográficos
Autor principal: Lin, Thomas S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513208/
https://www.ncbi.nlm.nih.gov/pubmed/23226042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513208/
https://www.ncbi.nlm.nih.gov/pubmed/23226042

Ejemplares similares